Deep brain stimulation for psychiatric refractory cases is last-line interventional treatment with specific indications, demanding infrastructure requirements, and meaningful but variable outcomes. The FDA Humanitarian Device Exemption supports DBS for severe refractory OCD; investigational use extends to TRD, addictions, Tourette syndrome, and other conditions. The clinical infrastructure required — neurosurgery with stereotactic expertise, psychiatry with DBS experience, programming specialists, ongoing multi-specialty care — concentrates the work in specialty centers and limits broad clinical access.
The indications and outcomes vary by condition. Severe refractory OCD has the most established DBS evidence — meaningful response rates (40–60% reduction in symptoms) in carefully selected patients who have failed extensive prior treatment. TRD DBS targeting the subgenual cingulate (BROADEN trial) and ventral capsule/ventral striatum has produced mixed results — clear responder subsets but failure to demonstrate efficacy in randomized trials sufficient for FDA approval. Tourette syndrome DBS has growing evidence for severe refractory cases. Addiction DBS is investigational with emerging signal.
The candidate selection is demanding. Patients must have severe refractory illness — typically multiple medication failures, adequate psychotherapy trials, often prior interventional treatments (TMS, ECT) tried inadequately. Psychiatric stability and capacity for informed consent. Adequate social support for the ongoing care requirements. Realistic expectations about outcomes — DBS can produce dramatic benefit in selected patients but is not curative; failure rates and partial-response rates are substantial. The candidate selection conversation is one of the most important clinical interactions; appropriate selection drives most of the outcome variance.
The surgical and ongoing care requirements are substantial. Stereotactic neurosurgery with precise targeting; bilateral lead placement; pulse generator placement. Programming sessions following surgery — initial programming weeks to months after recovery; ongoing programming adjustments over years. The programming work requires specialist expertise; many DBS centers have dedicated programming clinics. Hardware management — battery changes every several years for non-rechargeable systems; lead or hardware failures requiring revision; infection management. The lifetime care requirements substantially exceed conventional psychiatric treatment.
The longevity-psychiatry perspective. DBS for psychiatric refractory cases represents committing patients to ongoing intensive care across decades. The benefit when it occurs is meaningful — substantial reduction in severe symptoms, restored functioning, quality of life improvement. The commitment is real — the device-dependent state, the programming dependency, the surgical revision possibility. For patients with severe refractory illness producing substantial impairment, the trade-off may be worthwhile. The conversation needs to be thorough and ongoing.
The realistic clinical conversation. Most patients with severe refractory psychiatric illness will not be DBS candidates — the candidate selection is appropriately stringent. For appropriate candidates, DBS represents a meaningful option after extensive prior treatment. The path involves specialty center evaluation, comprehensive workup, informed consent processes that emphasize uncertainty and ongoing care, and integration with broader treatment continuing after surgery. The discipline is to recognize when DBS evaluation is appropriate, refer to centers with established DBS programs and adequate volume, support patients through what is a substantial clinical decision, and continue longitudinal care that integrates DBS with the broader treatment frame.